These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

611 related articles for article (PubMed ID: 34382294)

  • 1. WEE1 inhibitor and ataxia telangiectasia and RAD3-related inhibitor trigger stimulator of interferon gene-dependent immune response and enhance tumor treatment efficacy through programmed death-ligand 1 blockade.
    Wu X; Kang X; Zhang X; Xie W; Su Y; Liu X; Guo L; Guo E; Li F; Hu D; Qin X; Fu Y; Peng W; Jia J; Wang C
    Cancer Sci; 2021 Nov; 112(11):4444-4456. PubMed ID: 34382294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma.
    Sheng H; Huang Y; Xiao Y; Zhu Z; Shen M; Zhou P; Guo Z; Wang J; Wang H; Dai W; Zhang W; Sun J; Cao C
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic Co-targeting of WEE1 and ATM Downregulates PD-L1 Expression in Pancreatic Cancer.
    Jin MH; Nam AR; Park JE; Bang JH; Bang YJ; Oh DY
    Cancer Res Treat; 2020 Jan; 52(1):149-166. PubMed ID: 31291716
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Xu H; George E; Kinose Y; Kim H; Shah JB; Peake JD; Ferman B; Medvedev S; Murtha T; Barger CJ; Devins KM; D'Andrea K; Wubbenhorst B; Schwartz LE; Hwang WT; Mills GB; Nathanson KL; Karpf AR; Drapkin R; Brown EJ; Simpkins F
    Cell Rep Med; 2021 Sep; 2(9):100394. PubMed ID: 34622231
    [No Abstract]   [Full Text] [Related]  

  • 5. Inhibition of ATR Increases the Sensitivity to WEE1 Inhibitor in Biliary Tract Cancer.
    Nam AR; Jin MH; Bang JH; Oh KS; Seo HR; Oh DY; Bang YJ
    Cancer Res Treat; 2020 Jul; 52(3):945-956. PubMed ID: 32311864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined Inhibition of ATR and WEE1 as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer.
    Jin J; Fang H; Yang F; Ji W; Guan N; Sun Z; Shi Y; Zhou G; Guan X
    Neoplasia; 2018 May; 20(5):478-488. PubMed ID: 29605721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo.
    Chaudhuri L; Vincelette ND; Koh BD; Naylor RM; Flatten KS; Peterson KL; McNally A; Gojo I; Karp JE; Mesa RA; Sproat LO; Bogenberger JM; Kaufmann SH; Tibes R
    Haematologica; 2014 Apr; 99(4):688-96. PubMed ID: 24179152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential Activity of ATR and WEE1 Inhibitors in a Highly Sensitive Subpopulation of DLBCL Linked to Replication Stress.
    Young LA; O'Connor LO; de Renty C; Veldman-Jones MH; Dorval T; Wilson Z; Jones DR; Lawson D; Odedra R; Maya-Mendoza A; Reimer C; Bartek J; Lau A; O'Connor MJ
    Cancer Res; 2019 Jul; 79(14):3762-3775. PubMed ID: 31123088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibiting Wee1 and ATR kinases produces tumor-selective synthetic lethality and suppresses metastasis.
    Bukhari AB; Lewis CW; Pearce JJ; Luong D; Chan GK; Gamper AM
    J Clin Invest; 2019 Mar; 129(3):1329-1344. PubMed ID: 30645202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting MUS81 promotes the anticancer effect of WEE1 inhibitor and immune checkpoint blocking combination therapy via activating cGAS/STING signaling in gastric cancer cells.
    Li C; Shen Q; Zhang P; Wang T; Liu W; Li R; Ma X; Zeng X; Yin Y; Tao K
    J Exp Clin Cancer Res; 2021 Oct; 40(1):315. PubMed ID: 34625086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLC.
    Taniguchi H; Caeser R; Chavan SS; Zhan YA; Chow A; Manoj P; Uddin F; Kitai H; Qu R; Hayatt O; Shah NS; Quintanal Villalonga Á; Allaj V; Nguyen EM; Chan J; Michel AO; Mukae H; de Stanchina E; Rudin CM; Sen T
    Cell Rep; 2022 May; 39(7):110814. PubMed ID: 35584676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploiting replicative stress in gynecological cancers as a therapeutic strategy.
    Ngoi NY; Sundararajan V; Tan DS
    Int J Gynecol Cancer; 2020 Aug; 30(8):1224-1238. PubMed ID: 32571890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combining radiation and the ATR inhibitor berzosertib activates STING signaling and enhances immunotherapy via inhibiting SHP1 function in colorectal cancer.
    Liu C; Wang X; Qin W; Tu J; Li C; Zhao W; Ma L; Liu B; Qiu H; Yuan X
    Cancer Commun (Lond); 2023 Apr; 43(4):435-454. PubMed ID: 36855844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. WEE1 inhibition induces anti-tumor immunity by activating ERV and the dsRNA pathway.
    Guo E; Xiao R; Wu Y; Lu F; Liu C; Yang B; Li X; Fu Y; Wang Z; Li Y; Huang Y; Li F; Wu X; You L; Qin T; Lu Y; Huang X; Ma D; Mills GB; Sun C; Chen G
    J Exp Med; 2022 Jan; 219(1):. PubMed ID: 34825915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Depletion of ATR selectively sensitizes ATM-deficient human mammary epithelial cells to ionizing radiation and DNA-damaging agents.
    Cui Y; Palii SS; Innes CL; Paules RS
    Cell Cycle; 2014; 13(22):3541-50. PubMed ID: 25483091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment.
    Hardaker EL; Sanseviero E; Karmokar A; Taylor D; Milo M; Michaloglou C; Hughes A; Mai M; King M; Solanki A; Magiera L; Miragaia R; Kar G; Standifer N; Surace M; Gill S; Peter A; Talbot S; Tohumeken S; Fryer H; Mostafa A; Mulgrew K; Lam C; Hoffmann S; Sutton D; Carnevalli L; Calero-Nieto FJ; Jones GN; Pierce AJ; Wilson Z; Campbell D; Nyoni L; Martins CP; Baker T; Serrano de Almeida G; Ramlaoui Z; Bidar A; Phillips B; Boland J; Iyer S; Barrett JC; Loembé AB; Fuchs SY; Duvvuri U; Lou PJ; Nance MA; Gomez Roca CA; Cadogan E; Critichlow SE; Fawell S; Cobbold M; Dean E; Valge-Archer V; Lau A; Gabrilovich DI; Barry ST
    Nat Commun; 2024 Feb; 15(1):1700. PubMed ID: 38402224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of the ATR-CHK1 Pathway in Ewing Sarcoma Cells Causes DNA Damage and Apoptosis via the CDK2-Mediated Degradation of RRM2.
    Koppenhafer SL; Goss KL; Terry WW; Gordon DJ
    Mol Cancer Res; 2020 Jan; 18(1):91-104. PubMed ID: 31649026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological targeting the ATR-CHK1-WEE1 axis involves balancing cell growth stimulation and apoptosis.
    Mak JP; Man WY; Ma HT; Poon RY
    Oncotarget; 2014 Nov; 5(21):10546-57. PubMed ID: 25301733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting WEE1 Kinase in Gynecological Malignancies.
    Zhang W; Li Q; Yin R
    Drug Des Devel Ther; 2024; 18():2449-2460. PubMed ID: 38915863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells.
    Lloyd RL; Wijnhoven PWG; Ramos-Montoya A; Wilson Z; Illuzzi G; Falenta K; Jones GN; James N; Chabbert CD; Stott J; Dean E; Lau A; Young LA
    Oncogene; 2020 Jun; 39(25):4869-4883. PubMed ID: 32444694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.